Immediate Impact
3 by Nobel laureates 5 from Science/Nature 64 standout
Citing Papers
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Natural killer cell therapies
2024 StandoutNature
Works of M. Ravic being referenced
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
2015
Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL).
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| M. Ravic | 387 | 106 | 217 | 289 | 36 | 951 | |
| Jie Zhou | 323 | 98 | 260 | 289 | 79 | 1.1k | |
| J. Lawrence Werther | 115 | 37 | 432 | 334 | 29 | 886 | |
| Yongqian Shu | 395 | 34 | 137 | 457 | 40 | 1.0k | |
| Yurika Sugita | 350 | 26 | 255 | 436 | 28 | 1.1k | |
| Mohammed Najeeb Al Hallak | 444 | 19 | 151 | 620 | 53 | 1.2k | |
| Zhifang Jia | 301 | 46 | 196 | 324 | 55 | 913 | |
| D. J. Th. Wagener | 501 | 10 | 232 | 307 | 57 | 1.1k | |
| Jinglei Qu | 464 | 16 | 104 | 603 | 50 | 1.1k | |
| H. O. Klein | 329 | 23 | 239 | 165 | 39 | 1.0k | |
| Colin F. Spraggs | 299 | 319 | 150 | 427 | 48 | 1.1k |
All Works
Loading papers...